Shield Therapeutics PLC Results of 2024 Annual General Meeting

RNS Number : 2805T

Shield Therapeutics PLC

20 June 2024

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Results of 2024 Annual General Meeting

 

London, UK, 20 June 2024: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2024. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.

 

The following table shows the votes cast on each resolution:

 

	VOTES FOR	%	VOTES AGAINST	%	WITHHELD VOTES
Resolution 1	371,135,672	99.65%	1,321,765	0.35%	387,002
Resolution 2	367,256,140	98.70%	4,821,667	1.30%	766,632
Resolution 3	368,781,407	99.11%	3,296,400	0.89%	766,632
Resolution 4	368,781,161	99.11%	3,296,646	0.89%	766,632
Resolution 5	369,852,377	99.40%	2,225,430	0.60%	766,632
Resolution 6	369,852,377	99.39%	2,266,765	0.61%	725,297
Resolution 7	368,193,486	98.96%	3,884,321	1.04%	766,632
Resolution 8	371,077,210	99.63%	1,380,227	0.37%	387,002
Resolution 9	370,260,710	99.38%	2,293,669	0.62%	290,060
Resolution 10	368,304,167	98.90%	4,079,150	1.10%	461,122
Resolution 11	368,067,995	98.84%	4,305,730	1.16%	470,714
Resolution 12	367,071,290	98.53%	5,470,921	1.47%	302,228

 

Notes:

1.    Number of shares in issue 782,056,367.

2.    Details of the votes received on the resolutions are available on the Company's website:

https://www.shieldtherapeutics.com/corporate-documents/.

3.    Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

 

For further information please contact:

 

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO Santosh Shanbhag, CFO	[phone]
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel / Patrick Birkholm	[phone]
Joint Broker Cavendish Ltd Geoff Nash / George Dollemore/ Nigel Birks /Harriet Ward	[phone]
Financial PR & IR Advisor
Walbrook PR
Charlotte Edgar / Alice Woodings	[phone] or [e-mail]
Investor Contact (US Advisor) LifeSci Advisors, LLC Joyce Allaire	[e-mail]

 

About Iron Deficiency and Accrufer®/Feraccru®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.

 

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

 

About Shield Therapeutics plc

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialised in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and commercialisation of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. To learn more about Shield Therapeutics, see our website at www.shieldtherapeutics.com or follow us on LinkedIn and X.

 

Accrufer®/Feraccru® has patent coverage until the mid-2030s.

Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGZZGZVKGDGDZM